Original Research
Accepted on 13 Oct 2025
Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 13 Oct 2025
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 13 Oct 2025
in Clinical Diabetes
Original Research
Accepted on 13 Oct 2025
in Georeservoirs
Systematic Review
Accepted on 13 Oct 2025
in Cancer Endocrinology
Original Research
Accepted on 13 Oct 2025
in Geriatric Medicine
Original Research
Accepted on 13 Oct 2025
in Heart Failure and Transplantation
Original Research
Accepted on 13 Oct 2025
in Nutritional Epidemiology
Correction
Accepted on 13 Oct 2025
in Sport Psychology
Original Research
Accepted on 13 Oct 2025
in Inflammation Pharmacology
Original Research
Accepted on 13 Oct 2025
in Neurogenomics
Review
Accepted on 13 Oct 2025
in Computational Genomics
Editorial
Accepted on 13 Oct 2025
in Plant Biotechnology
Original Research
Accepted on 13 Oct 2025
in Quantitative Psychology and Measurement
Case Report
Accepted on 13 Oct 2025
in Hematology
Original Research
Accepted on 13 Oct 2025
in Cognitive Science
Original Research
Accepted on 13 Oct 2025
in Quantitative Psychology and Measurement